appointment of Dr. Gabriel Capellá as director of IDIBELL.
Researchers from the proCURE ICO-IDIBELL breast cancer research group have first described why tumors adapt to and resist therapy with mTOR inhibitors, a treatment used in advanced stages of this cancer. The results of this international study, published in the journal Oncogene, sets new steps towards a more personalized selection of cancer therapies. The mTOR
Researchers of the TGF-beta and Cancer group of Bellvitge Biomedical Research Institute (IDIBELL), in collaboration with King’s College London, have unveiled the role of NADPH oxidase NOX4 as an inhibitor of the epithelial-amoeboid transition, a process that contributes to the migration and invasion of tumor cells. The study has just been published in the journal
The City Council and the research center join forces to raise funds against intellectual disability 100 years Sinatra
Removal of antibodies with glycoconjugates Valuation and commercialisation, pending challenges
On November 10th, the Bellvitge Biomedical Research Institute (IDIBELL) was awarded the “Company with Value” badge by Vàlua entities. This award rewards the collaboration and commitment of IDIBELL with this platform and with equal opportunities of all people. A “Company with Value” is a company committed to citizenship: a company that cares about the well-being
Researchers of the Sarcoma research group of the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr. Òscar Martínez-Tirado, have first described the methylation profile of Ewing’s sarcoma (ES), a cancer of bone and soft tissues that mainly affects children and teenagers. Their analysis has unveiled the potential of the PTRF gene as a prognostic marker